Pliant Therapeutics (PLRX) Total Current Liabilities (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Total Current Liabilities of $10.4 million for Q1 2026, down 63.27% year-over-year from $28.2 million in Q1 2025, and down 36.7% quarter-over-quarter from $16.4 million in Q4 2025.
Pliant Therapeutics (PLRX) Total Current Liabilities (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Total Current Liabilities for 8 consecutive years, with $10.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 63.27% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (down 63.27% YoY), while the FY2025 annual figure was $16.4 million, down 50.73% from the prior year.
- Total Current Liabilities slipped to $10.4 million in Q1 2026 per PLRX's latest filing, from $16.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $40.0 million in Q3 2024 and bottomed at $10.4 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $25.1 million across 5 years, with a median of $26.2 million in 2022.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 106.3% — and 2026, when it slumped 63.27%.
- Pliant Therapeutics' Total Current Liabilities stood at $23.9 million in 2022, then increased by 19.28% to $28.5 million in 2023, then climbed by 16.46% to $33.2 million in 2024, then tumbled by 50.73% to $16.4 million in 2025, then plunged by 36.7% to $10.4 million in 2026.
- Business Quant data shows PLRX's Total Current Liabilities at $10.4 million in Q1 2026, $16.4 million in Q4 2025, and $17.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 16.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.48 Mn |
| Mar 31, 2026 | 10.36 Mn |
| Dec 31, 2025 | 16.37 Mn |
| Sep 30, 2025 | 17.62 Mn |
| Jun 30, 2025 | 20.59 Mn |
| Mar 31, 2025 | 28.20 Mn |
| Dec 31, 2024 | 33.22 Mn |
| Sep 30, 2024 | 39.95 Mn |
| Jun 30, 2024 | 30.92 Mn |
| Mar 31, 2024 | 30.39 Mn |
| Dec 31, 2023 | 28.52 Mn |
| Sep 30, 2023 | 27.40 Mn |
| Jun 30, 2023 | 29.52 Mn |
| Mar 31, 2023 | 23.15 Mn |
| Dec 31, 2022 | 23.91 Mn |
| Sep 30, 2022 | 26.16 Mn |
| Jun 30, 2022 | 22.55 Mn |
| Mar 31, 2022 | 18.31 Mn |
| Dec 31, 2021 | 16.83 Mn |
| Sep 30, 2021 | 12.93 Mn |